Archives of Endocrinology and Metabolism (May 2018)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

  • Debora L. S. Danilovic,
  • Gilberto Castro Jr.,
  • Felipe S. R. Roitberg,
  • Felipe A. B. Vanderlei,
  • Fernanda A. Bonani,
  • Ricardo M. C. Freitas,
  • George B. Coura-Filho,
  • Rosalinda Y. Camargo,
  • Marco A. Kulcsar,
  • Suemi Marui,
  • Ana O. Hoff

DOI
https://doi.org/10.20945/2359-3997000000046
Journal volume & issue
Vol. 62, no. 3
pp. 370 – 375

Abstract

Read online

Summary Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.